APX3330 reverses the immunosuppressive tumor microenvironment during colorectal carcinogenesis.

Cancer Cell Int · 2026 · PMC12895612 · PMID 41547851

Europe PMC DOI

hedged sentences

0.0680

closest p · 1.4× alpha

0.0680

boldest claim

The sentences

reached borderline significanceP = 0.068so close (0.05 < p ≤ 0.1)

The prognosis analysis in GSE39582 (see Supplementary Table 4 for baseline characteristics) revealed that the APX3330-resolution score were significantly associated with an increased risk of recurrence in the univariate Cox regression (HR = 1.148, 95% CI: 1.054–2.081, P = 0.024) but only reached borderline significance after adjusted for other clinical factors (HR = 1.388, 95% CI: 0.976–1.974, P = 0.068) (Fig. 6 C-D).

also in 93 other papers

did not reach statistical significanceno p-value reported

Furthermore, following treatment with APX3330, the levels of IL-10 (FC = 0.5393), CCL22 (FC = 0.1294), CCL24 (FC = 0.0131), CCL26 (FC = 0.8034), CCL20 (FC = 0.0399), and CXCL11 (FC = 0.4791) exhibited a decrease, the expressions of CX3CL1 (FC = 1.1724) and MIF (FC = 1.1632) showed an increase; however, these changes did not reach statistical significance.

also in 50,127 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.